Published in Lancet on July 06, 2002
Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med (2007) 19.78
Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS (2008) 13.25
Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries. Bull World Health Organ (2008) 8.70
Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. Clin Infect Dis (2008) 5.14
Rapid scaling-up of antiretroviral therapy in 10,000 adults in Côte d'Ivoire: 2-year outcomes and determinants. AIDS (2008) 4.40
Overestimates of survival after HAART: implications for global scale-up efforts. PLoS One (2008) 4.20
HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS (2007) 3.94
Five-year outcomes of initial patients treated in Botswana's National Antiretroviral Treatment Program. AIDS (2008) 3.71
Can highly active antiretroviral therapy reduce the spread of HIV?: A study in a township of South Africa. J Acquir Immune Defic Syndr (2004) 3.19
Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med (2005) 3.17
Barriers to accessing highly active antiretroviral therapy by HIV-positive women attending an antenatal clinic in a regional hospital in western Uganda. J Int AIDS Soc (2010) 3.03
Cost-effectiveness of highly active antiretroviral therapy in South Africa. PLoS Med (2005) 3.01
Rationale and uses of a public HIV drug-resistance database. J Infect Dis (2006) 2.91
Early mortality in adults initiating antiretroviral therapy (ART) in low- and middle-income countries (LMIC): a systematic review and meta-analysis. PLoS One (2011) 2.84
Two-year virologic outcomes of an alternative AIDS care model: evaluation of a peer health worker and nurse-staffed community-based program in Uganda. J Acquir Immune Defic Syndr (2009) 2.62
Modelling the impact of antiretroviral use in resource-poor settings. PLoS Med (2006) 2.52
The impact of gender and income on survival and retention in a South African antiretroviral therapy programme. Trop Med Int Health (2009) 2.48
Antiretroviral therapy at a district hospital in Ethiopia prevents death and tuberculosis in a cohort of HIV patients. AIDS Res Ther (2006) 2.08
Four-year treatment outcomes of adult patients enrolled in Mozambique's rapidly expanding antiretroviral therapy program. PLoS One (2011) 2.05
Impact of drug stock-outs on death and retention to care among HIV-infected patients on combination antiretroviral therapy in Abidjan, Côte d'Ivoire. PLoS One (2010) 2.05
Antiretroviral treatment roll-out in a resource-constrained setting: capitalizing on nursing resources in Botswana. Bull World Health Organ (2007) 2.02
Low retention of HIV-infected patients on antiretroviral therapy in 11 clinical centres in West Africa. Trop Med Int Health (2010) 2.00
Impact of genotypic drug resistance mutations on clinical and immunological outcomes in HIV-infected adults on HAART in West Africa. AIDS (2007) 1.97
A national survey of teachers on antiretroviral therapy in Malawi: access, retention in therapy and survival. PLoS One (2007) 1.80
Predictors of mortality among HIV infected patients taking antiretroviral treatment in Ethiopia: a retrospective cohort study. AIDS Res Ther (2012) 1.50
Risk factors for virological failure and subtherapeutic antiretroviral drug concentrations in HIV-positive adults treated in rural northwestern Uganda. BMC Infect Dis (2009) 1.50
Outcomes of antiretroviral treatment program in Ethiopia: retention of patients in care is a major challenge and varies across health facilities. BMC Health Serv Res (2011) 1.47
Gender differences in retention and survival on antiretroviral therapy of HIV-1 infected adults in Malawi. Malawi Med J (2010) 1.46
Response to zidovudine/didanosine-containing combination antiretroviral therapy among HIV-1 subtype C-infected adults in Botswana: two-year outcomes from a randomized clinical trial. J Acquir Immune Defic Syndr (2009) 1.45
Mortality and virologic outcomes after access to antiretroviral therapy among a cohort of HIV-infected women who received single-dose nevirapine in Lusaka, Zambia. J Acquir Immune Defic Syndr (2009) 1.40
Lessons learned while implementing an HIV/AIDS care and treatment program in rural Mozambique. Retrovirology (Auckl) (2010) 1.36
Virological efficacy and emergence of drug resistance in adults on antiretroviral treatment in rural Tanzania. BMC Infect Dis (2009) 1.33
Low haemoglobin predicts early mortality among adults starting antiretroviral therapy in an HIV care programme in South Africa: a cohort study. BMC Public Health (2010) 1.30
Determining eligibility for antiretroviral therapy in resource-limited settings using total lymphocyte counts, hemoglobin and body mass index. AIDS Res Ther (2007) 1.30
Non-nucleoside reverse transcriptase inhibitor outcomes among combination antiretroviral therapy-treated adults in Botswana. AIDS (2010) 1.28
Sub-optimal CD4 reconstitution despite viral suppression in an urban cohort on antiretroviral therapy (ART) in sub-Saharan Africa: frequency and clinical significance. AIDS Res Ther (2008) 1.22
Evaluation of an ultrasensitive p24 antigen assay as a potential alternative to human immunodeficiency virus type 1 RNA viral load assay in resource-limited settings. J Clin Microbiol (2005) 1.21
High efficacy of lopinavir/r-based second-line antiretroviral treatment after 24 months of follow up at ESTHER/Calmette Hospital in Phnom Penh, Cambodia. J Int AIDS Soc (2011) 1.21
HIV treatment and care in resource-constrained environments: challenges for the next decade. J Int AIDS Soc (2012) 1.21
Eligibility for HIV/AIDS treatment among adults in a medical emergency setting at an urban hospital in Uganda. Afr Health Sci (2007) 1.11
Retention in an antiretroviral therapy programme during an era of decreasing drug cost in Limbe, Cameroon. J Int AIDS Soc (2011) 1.07
The emergence of HIV transmitted resistance in Botswana: "when will the WHO detection threshold be exceeded?". PLoS One (2007) 1.04
Antiretroviral treatment for HIV in rural Uganda: two-year treatment outcomes of a prospective health centre/community-based and hospital-based cohort. PLoS One (2012) 1.03
The effect of AIDS defining conditions on immunological recovery among patients initiating antiretroviral therapy at Joint Clinical Research Centre, Uganda. AIDS Res Ther (2009) 0.98
Correlates of HIV-1 viral suppression in a cohort of HIV-positive drug users receiving antiretroviral therapy in Hanoi, Vietnam. Int J STD AIDS (2009) 0.98
A clinician-nurse model to reduce early mortality and increase clinic retention among high-risk HIV-infected patients initiating combination antiretroviral treatment. J Int AIDS Soc (2012) 0.98
Predictors of Loss to follow-up in Patients Living with HIV/AIDS after Initiation of Antiretroviral Therapy. N Am J Med Sci (2014) 0.97
Implementation and operational research: Integrated pre-antiretroviral therapy screening and treatment for tuberculosis and cryptococcal antigenemia. J Acquir Immune Defic Syndr (2015) 0.96
Characteristics, immunological response & treatment outcomes of HIV-2 compared with HIV-1 & dual infections (HIV 1/2) in Mumbai. Indian J Med Res (2010) 0.95
Determinants of retention in care in an antiretroviral therapy (ART) program in urban Cameroon, 2003-2005. Pan Afr Med J (2008) 0.93
Hepatotoxicity from first line antiretroviral therapy: an experience from a resource limited setting. Afr Health Sci (2011) 0.92
Barriers to use of antiretroviral drugs in Rakai district of Uganda. Afr Health Sci (2010) 0.91
Plasma levels of soluble urokinase-type plasminogen activator receptor (suPAR) and early mortality risk among patients enrolling for antiretroviral treatment in South Africa. BMC Infect Dis (2007) 0.90
Comparing antiretroviral treatment outcomes between a prospective community-based and hospital-based cohort of HIV patients in rural Uganda. BMC Int Health Hum Rights (2011) 0.89
Effects of physical tracing on estimates of loss to follow-up, mortality and retention in low and middle income country antiretroviral therapy programs: a systematic review. PLoS One (2013) 0.89
Predictors of Mortality among Adult Antiretroviral Therapy Users in Southeastern Ethiopia: Retrospective Cohort Study. AIDS Res Treat (2015) 0.85
The global status of HIV drug resistance: clinical and public-health approaches for detection, treatment and prevention. Infect Disord Drug Targets (2011) 0.84
Retention in HIV Care and Predictors of Attrition from Care among HIV-Infected Adults Receiving Combination Anti-Retroviral Therapy in Addis Ababa. PLoS One (2015) 0.84
Antiretroviral therapy in resource-poor countries: illusions and realities. Am J Public Health (2005) 0.84
Adult combination antiretroviral therapy in sub-Saharan Africa: lessons from Botswana and future challenges. HIV Ther (2009) 0.83
Assessment of the impact of adherence and other predictors during HAART on various CD4 cell responses in resource-limited settings. Patient Prefer Adherence (2012) 0.83
The HIV-1 Non-subtype B Workgroup: an international collaboration for the collection and analysis of HIV-1 non-subtype B data. MedGenMed (2005) 0.83
Qualitative study of changes in alcohol use among HIV-infected adults entering care and treatment for HIV/AIDS in rural southwest Uganda. AIDS Behav (2015) 0.82
Estimating the capacity for ART provision in Tanzania with the use of data on staff productivity and patient losses. PLoS One (2009) 0.82
Association between Highly Active Antiretroviral Therapy and Type of Infectious Respiratory Disease and All-Cause In-Hospital Mortality in Patients with HIV/AIDS: A Case Series. PLoS One (2015) 0.81
CD4 T-cell activation and reduced regulatory T-cell populations are associated with early development of cataracts among HIV-infected adults in Uganda. Immunol Lett (2014) 0.80
Poor efficacy and tolerability of stavudine, didanosine, and efavirenz-based regimen in treatment-naive patients in Senegal. MedGenMed (2007) 0.79
Poor immunological recovery among severely immunosuppressed antiretroviral therapy-naïve Ugandans. HIV AIDS (Auckl) (2013) 0.79
Drug resistance mutations in HIV type 1 isolates from patients failing antiretroviral therapy in Morocco. AIDS Res Hum Retroviruses (2011) 0.77
The HIV-1 Non-subtype B Workgroup: An International Collaboration for the Collection and Analysis of HIV-1 Non-subtype B Data. J Int AIDS Soc (2005) 0.77
Therapeutic immunization in HIV infected Ugandans receiving stable antiretroviral treatment: a Phase I safety study. Vaccine (2011) 0.77
Assessment of antiretroviral therapy knowledge and willingness of persons with HIV to support its uptake in Uganda. Patient Prefer Adherence (2011) 0.75
Poor Efficacy and Tolerability of Stavudine, Didanosine, and Efavirenz-based Regimen in Treatment-Naive Patients in Senegal. J Int AIDS Soc (2007) 0.75
Development and validation of a clinical score for prognosis stratification in patients requiring antiretroviral therapy in sub-Saharan Africa: a prospective open cohort study. Pan Afr Med J (2011) 0.75
Predictors of Survival among Adult Ethiopian Patients in the National ART Program at Seven University Teaching Hospitals: A Prospective Cohort Study. Ethiop J Health Sci (2017) 0.75
Patient outcome in adults with pneumococcal meningitis or bacteraemia admitted to QECH. Malawi Med J (2003) 0.75
Effective coverage for antiretroviral therapy in a Ugandan district with a decentralized model of care. PLoS One (2013) 0.75
Immunological profile in persons under antiretroviral therapy in a rural Nigerian hospital. J Public Health Africa (2010) 0.75
Evaluation of antiretroviral therapy results in Blantyre, Malawi. Malawi Med J (2005) 0.75
Estimated HIV incidence in the United States, 2006-2009. PLoS One (2011) 13.03
An assessment of interactions between global health initiatives and country health systems. Lancet (2009) 10.53
Changes in sexual behavior and risk of HIV transmission after antiretroviral therapy and prevention interventions in rural Uganda. AIDS (2006) 9.45
Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med (2011) 6.42
Newly discovered ebola virus associated with hemorrhagic fever outbreak in Uganda. PLoS Pathog (2008) 6.07
Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. AIDS (2007) 5.97
Rapid diagnosis of Ebola hemorrhagic fever by reverse transcription-PCR in an outbreak setting and assessment of patient viral load as a predictor of outcome. J Virol (2004) 5.86
Differences in human immunodeficiency virus care and treatment among subpopulations in the United States. JAMA Intern Med (2013) 5.39
Adherence to antiretroviral therapy in a home-based AIDS care programme in rural Uganda. Lancet (2006) 5.34
Risk factors for recent HIV infection in Uganda. JAMA (2008) 4.84
Mortality in HIV-infected Ugandan adults receiving antiretroviral treatment and survival of their HIV-uninfected children: a prospective cohort study. Lancet (2008) 4.70
Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting. J Acquir Immune Defic Syndr (2004) 4.58
Isolation of genetically diverse Marburg viruses from Egyptian fruit bats. PLoS Pathog (2009) 4.56
Prevalence, incidence and mortality associated with tuberculosis in HIV-infected patients initiating antiretroviral therapy in rural Uganda. AIDS (2007) 4.52
The costs and effectiveness of four HIV counseling and testing strategies in Uganda. AIDS (2009) 4.45
Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial. Lancet (2009) 4.33
Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet (2004) 4.19
Transmission of HIV-1 infection in sub-Saharan Africa and effect of elimination of unsafe injections. Lancet (2004) 4.13
Population-based hematologic and immunologic reference values for a healthy Ugandan population. Clin Diagn Lab Immunol (2004) 3.92
Transmission of human herpesvirus 8 by blood transfusion. N Engl J Med (2006) 3.80
Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda. Trop Med Int Health (2007) 3.69
Reproductive intentions and outcomes among women on antiretroviral therapy in rural Uganda: a prospective cohort study. PLoS One (2009) 3.66
HIV transmission risk behavior among HIV-infected adults in Uganda: results of a nationally representative survey. AIDS (2008) 3.52
Unfinished business--expanding HIV testing in developing countries. N Engl J Med (2006) 3.48
Performance of immunologic responses in predicting viral load suppression: implications for monitoring patients in resource-limited settings. J Acquir Immune Defic Syndr (2006) 3.38
Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Côte d'Ivoire. AIDS (2003) 3.37
Disclosure of HIV status and adherence to daily drug regimens among HIV-infected children in Uganda. AIDS Behav (2006) 3.18
Depletion of regulatory T cells in HIV infection is associated with immune activation. J Immunol (2005) 3.00
Comparison of home and clinic-based HIV testing among household members of persons taking antiretroviral therapy in Uganda: results from a randomized trial. J Acquir Immune Defic Syndr (2010) 2.83
Processes and outcomes of HIV serostatus disclosure to sexual partners among people living with HIV in Uganda. AIDS Behav (2007) 2.78
Routine intrapartum HIV counseling and testing for prevention of mother-to-child transmission of HIV in a rural Ugandan hospital. J Acquir Immune Defic Syndr (2006) 2.67
Morbidity and mortality in South African gold miners: impact of untreated disease due to human immunodeficiency virus. Clin Infect Dis (2002) 2.60
Desire for children and pregnancy risk behavior among HIV-infected men and women in Uganda. AIDS Behav (2006) 2.59
Home-based model for HIV voluntary counselling and testing. Lancet (2003) 2.57
Expanding HIV care in Africa: making men matter. Lancet (2009) 2.54
HIV prevention for a threatened continent: implementing positive prevention in Africa. JAMA (2006) 2.51
Cotrimoxazole prophylaxis by HIV-infected persons in Uganda reduces morbidity and mortality among HIV-uninfected family members. AIDS (2005) 2.50
Antiretroviral therapy improves renal function among HIV-infected Ugandans. Kidney Int (2008) 2.49
Antiretroviral therapy and sexual behavior: a comparative study between antiretroviral- naive and -experienced patients at an urban HIV/AIDS care and research center in Kampala, Uganda. AIDS Patient Care STDS (2005) 2.48
Antiretroviral treatment in resource-poor settings: clinical research priorities. Lancet (2002) 2.36
CD4+ T-cell count monitoring does not accurately identify HIV-infected adults with virologic failure receiving antiretroviral therapy. J Acquir Immune Defic Syndr (2008) 2.32
Retention in care of adults and adolescents living with HIV in 13 U.S. areas. J Acquir Immune Defic Syndr (2012) 2.15
Effect of home-based water chlorination and safe storage on diarrhea among persons with human immunodeficiency virus in Uganda. Am J Trop Med Hyg (2005) 2.12
Rapid implementation of an integrated large-scale HIV counseling and testing, malaria, and diarrhea prevention campaign in rural Kenya. PLoS One (2010) 2.12
Lack of knowledge of HIV status a major barrier to HIV prevention, care and treatment efforts in Kenya: results from a nationally representative study. PLoS One (2012) 2.10
Estimating per-act HIV transmission risk: a systematic review. AIDS (2014) 2.04
Prevalence, incidence and predictors of severe anaemia with zidovudine-containing regimens in African adults with HIV infection within the DART trial. Antivir Ther (2006) 2.02
Depression and CD4 cell count among persons with HIV infection in Uganda. AIDS Behav (2006) 2.01
Assessment of second-line antiretroviral regimens for HIV therapy in Africa. N Engl J Med (2014) 2.00
Seasonal pulses of Marburg virus circulation in juvenile Rousettus aegyptiacus bats coincide with periods of increased risk of human infection. PLoS Pathog (2012) 2.00
Ebola virus disease in health care workers--Sierra Leone, 2014. MMWR Morb Mortal Wkly Rep (2014) 1.99
Home-based HIV testing and counseling in rural and urban Kenyan communities. J Acquir Immune Defic Syndr (2013) 1.98
Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy. Clin Infect Dis (2008) 1.98
Clinical toxicity of highly active antiretroviral therapy in a home-based AIDS care program in rural Uganda. J Acquir Immune Defic Syndr (2007) 1.97
CD4 cell count and viral load monitoring in patients undergoing antiretroviral therapy in Uganda: cost effectiveness study. BMJ (2011) 1.96
Use of antiretroviral therapy in resource-limited countries in 2006: distribution and uptake of first- and second-line regimens. AIDS (2007) 1.94
The cost effectiveness of home-based provision of antiretroviral therapy in rural Uganda. Appl Health Econ Health Policy (2009) 1.94
Cryptosporidiosis and microsporidiosis in ugandan children with persistent diarrhea with and without concurrent infection with the human immunodeficiency virus. Am J Trop Med Hyg (2005) 1.90
Scale-up of HIV treatment through PEPFAR: a historic public health achievement. J Acquir Immune Defic Syndr (2012) 1.78
Proportion of deaths and clinical features in Bundibugyo Ebola virus infection, Uganda. Emerg Infect Dis (2010) 1.75
Factors associated with HIV infection in married or cohabitating couples in Kenya: results from a nationally representative study. PLoS One (2011) 1.68
T cell activation in HIV-seropositive Ugandans: differential associations with viral load, CD4+ T cell depletion, and coinfection. J Infect Dis (2005) 1.63
Effect of cotrimoxazole on mortality in HIV-infected adults on antiretroviral therapy: a systematic review and meta-analysis. Bull World Health Organ (2011) 1.61
Sexual risk behaviour and viral suppression among HIV-infected adults receiving medical care in the United States. AIDS (2014) 1.61
Long-term experience providing antiretroviral drugs in a fee-for-service HIV clinic in Uganda: evidence of extended virologic and CD4+ cell count responses. J Acquir Immune Defic Syndr (2005) 1.59
HIV/AIDS treatment and HIV vaccines for Africa. Lancet (2002) 1.58
Epidemiology of HIV in the United States. J Acquir Immune Defic Syndr (2010) 1.58
Impact of HIV antiretroviral therapy on depression and mental health among clients with HIV in Uganda. Psychosom Med (2012) 1.58
High prevalence of antiretroviral resistance in treated Ugandans infected with non-subtype B human immunodeficiency virus type 1. AIDS Res Hum Retroviruses (2004) 1.58
Estimating HIV incidence among adults in Kenya and Uganda: a systematic comparison of multiple methods. PLoS One (2011) 1.56
Hepatitis B infection is highly endemic in Uganda: findings from a national serosurvey. Afr Health Sci (2009) 1.56
Tuberculosis in Bissau: incidence and risk factors in an urban community in sub-Saharan Africa. Int J Epidemiol (2004) 1.54
Home-based antiretroviral care is associated with positive social outcomes in a prospective cohort in Uganda. J Acquir Immune Defic Syndr (2007) 1.52
Use of a nationwide call center for Ebola response and monitoring during a 3-day house-to-house campaign - Sierra Leone, September 2014. MMWR Morb Mortal Wkly Rep (2015) 1.52
Efficacy of secondary isoniazid preventive therapy among HIV-infected Southern Africans: time to change policy? AIDS (2003) 1.51
Changes in lipid profile over 24 months among adults on first-line highly active antiretroviral therapy in the home-based AIDS care program in rural Uganda. J Acquir Immune Defic Syndr (2008) 1.51